The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Optimization of Voyager V1 (VV1) oncolytic virus systemic delivery in combination with cemiplimab and ipilimumab in patients with melanoma and non–small cell lung cancer (NSCLC).
 
Jose Lutzky
Consulting or Advisory Role - Castle Biosciences; Eisai; Iovance Biotherapeutics; Sapience Therapeutics
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); InflarxGmbH (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst); Ultimovacs (Inst); Vyriad (Inst)
 
Thomas Urban Marron
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celldex; DBV Technologies; Glenmark; NGM Biopharmaceuticals; Regeneron; Surface Oncology
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the combined use of IL4 blockade and PD-1 blockade. (Inst); Patient on the neoadjuvant use of cemiplimab for the treatment of HCC
 
Steven Francis Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Research Funding - Actuate Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Vyriad (Inst)
 
Daniel H. Johnson
Leadership - BrightPath Biotheraputics
Honoraria - BrightPath Biotheraputics
Speakers' Bureau - Bristol-Myers Squibb/Pfizer
 
Manish Patel
Consulting or Advisory Role - Nektar
Research Funding - AstraZeneca/MedImmune; Fate Therapeutics; Merck KGaA; Vyriad
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Roche/Genentech; SERVIER; Tallac Therapeutics
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Roche; SERVIER; Tallac Therapeutics
Research Funding - Astex Pharmaceuticals; AstraZeneca; Fulgent Genetics
 
John Sarantopoulos
No Relationships to Disclose
 
Saida Dadi-Mehmetaj
Employment - Regeneron
 
Luke Russell
Employment - Vyriad
Leadership - Vyriad (I)
Stock and Other Ownership Interests - Vyriad
Patents, Royalties, Other Intellectual Property - Oncolytic Virus expressing PTEN-alpha
 
Stephen J. Russell
Stock and Other Ownership Interests - Imanis Life Sciences; Vyriad
Patents, Royalties, Other Intellectual Property - As a Mayo Clinic employee I have filed invention disclosures and some of those have been filed as patents. I have assigned my rights in those patents to Mayo Clinic. (Inst)
Travel, Accommodations, Expenses - Vyriad
 
Kah Whye Peng
Employment - Imanis Life Sciences; Vyriad
Leadership - Imanis Life Sciences; Vyriad
Stock and Other Ownership Interests - Imanis Life Sciences; Vyriad
 
Stephen Kaesshaefer
No Relationships to Disclose
 
Giuseppe Gullo
Employment - Regeneron
 
Alice Susannah Bexon
Employment - Bexon Clinical Consulting
Leadership - Sapience Therapeutics; Vyriad
Stock and Other Ownership Interests - Sapience Therapeutics; Vyriad
Patents, Royalties, Other Intellectual Property - Patents for Sapience know-how relative to ST101
Travel, Accommodations, Expenses - Sapience Therapeutics; Vyriad
 
Mario Sznol
Stock and Other Ownership Interests - Actym Therapeutics; Adaptive Biotechnologies; Amphivena; EvolveImmune Therapeutics; GlaxoSmithKline; Intensity Therapeutics; Johnson & Johnson/Janssen; Nextcure; Torque
Consulting or Advisory Role - Abbvie; Adaptimmune; Agenus; Alligator Bioscience; Anaeropharma; AstraZeneca/MedImmune; BioNTech; Boehringer Ingelheim; Boston Pharmaceuticals; Bristol-Myers Squibb; Dragonfly Therapeutics; Genentech/Roche; Genocea Biosciences; Gilead Sciences; immunocore; Innate Pharma; ITeos Therapeutics; Jazz Pharmaceuticals; Lilly; Molecular Partners; Nektar; Numab; OncoSec; Pfizer; Pieris Pharmaceuticals; Pierre Fabre; Sapience Therapeutics; Seagen; SERVIER; Simcha Therapeutics; ST Cube; Targovax; Tessa Therapeutics; Trillium Therapeutics; Verastem; Zelluna
Other Relationship - CEC Oncology; Dava Oncology; Haymarket Media; Physicans' Education Resource